# Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

> **NCT05403723** · PHASE1 · SUSPENDED · sponsor: **University of Maryland, Baltimore** · enrollment: 50 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab 50 MG/1 ML Intravenous Solution
- **DRUG:** Etoposide Injection
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DEVICE:** Stereotactic Body Radiotherapy

## Key facts

- **NCT ID:** NCT05403723
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2026-06-30
- **Primary completion:** 2027-02
- **Final completion:** 2027-08
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** PI changed institution. Not yet approved at current location.
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403723, "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05403723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*